Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sihuan Pharma Announces Second Anti-Virus Partnership with AMMS

publication date: Oct 17, 2014
Sihuan Pharma announced a second anti-viral collaboration with the Institute of Microbiology and Epidemiology of the Academy of Military Medical Sciences (AMMS). The newest project involves BR-01, an anti-adenovirus drug. The collaboration follows less than a week behind an agreement between Sihuan and AMMS for joint development of an AMMS-developed Ebola treatment. Sihuan expects BR-01 will prove effective as both a preventative and treatment for a broad spectrum of virus-caused illnesses. Financial terms of the collaboration were not made public. More details....

Stock Symbol: (HK 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital